Correction to: British Journal of Cancer (2023) 128:2326-2337; https://doi.org/10.1038/s41416-023-02252-8, Article published online 19 April 2023
Following the original publication, the authors were notified of an error present in Figure 1, specifically Figure 1bii, where the same image file was used for CDK4 and CDK7.
The corrected version of Figure 1 is produced here.
The authors provided the journal with the original data. The correction does not have any effect on the results or conclusions of the paper.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Constantin, T.A., Varela-Carver, A., Greenland, K.K. et al. Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer 130, 892 (2024). https://doi.org/10.1038/s41416-024-02606-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-024-02606-w
